RESUMEN
BACKGROUND: This prospective study was conducted to evaluate the feasibility and safety of customized chemotherapy regimens based on the gene characteristics of salivary gland tumors. METHODS: Patients were enrolled with histologically confirmed intermediate or high grade, stage T3-4, N1-3 disease, and T1-2, N0 patients with a close (≤1âmm) or microscopically positive surgical margin were also enrolled in the study. All patients received radical surgery and postoperative concurrent chemoradiotherapy. To evaluate the responsiveness of therapies, the chemotherapy regimen was based on gene targets, ß-tubulin III, ABCB1, STMN1, and CYP1B1 (for docetaxel) and TYMS (for pemetrexed). The primary endpoints were treatment compliance and acute toxicities. RESULTS: A total of 20 patients were enrolled between September 2013 and January 2016. The median age was 46 years (range: 23-70 years). Genetic testing showed that 8 patients may have been sensitive to docetaxel, 5 patients may have been sensitive to pemetrexed, and 7 patients sensitive to either docetaxel or pemetrexed. All patients received the full dose of radiation. A total of 19 patients (95%) completed 2 cycles of concurrent chemotherapy (CCT). One patient treated concurrently with pemetrexed experienced grade 3 neutropenia. Three patients experienced grade 3 oral mucositis, and 2 patients experienced grade 3 dermatitis. CONCLUSION: Our study demonstrated that a CCT selecting method based on the gene targets associated with drug sensitivity was clinically feasible and safe. Further studies enrolled more patients with longer follow-up times are needed to confirm the clinical efficacy of this CCT selecting method.
Asunto(s)
Antineoplásicos/uso terapéutico , Marcación de Gen/métodos , Pruebas Genéticas/métodos , Selección de Paciente , Neoplasias de las Glándulas Salivales/terapia , Subfamilia B de Transportador de Casetes de Unión a ATP/análisis , Subfamilia B de Transportador de Casetes de Unión a ATP/efectos de los fármacos , Adulto , Anciano , Antineoplásicos/administración & dosificación , Quimioradioterapia/métodos , Citocromo P-450 CYP1B1/análisis , Citocromo P-450 CYP1B1/efectos de los fármacos , Docetaxel , Estudios de Factibilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pemetrexed/administración & dosificación , Estudios Prospectivos , Neoplasias de las Glándulas Salivales/genética , Estatmina/análisis , Estatmina/efectos de los fármacos , Taxoides/administración & dosificación , Timidilato Sintasa/análisis , Timidilato Sintasa/efectos de los fármacos , Tubulina (Proteína)/análisis , Tubulina (Proteína)/efectos de los fármacos , Adulto JovenRESUMEN
Cytochrome P450 1B1 protects against angiotensin II (Ang II)-induced hypertension and associated cardiovascular changes in female mice, most likely via production of 2-methoxyestradiol. This study was conducted to determine whether 2-methoxyestradiol ameliorates Ang II-induced hypertension, renal dysfunction, and end-organ damage in intact Cyp1b1-/-, ovariectomized female, and Cyp1b1+/+ male mice. Ang II or vehicle was infused for 2 weeks and administered concurrently with 2-methoxyestradiol. Mice were placed in metabolic cages on day 12 of Ang II infusion for urine collection for 24 hours. 2-Methoxyestradiol reduced Ang II-induced increases in systolic blood pressure, water consumption, urine output, and proteinuria in intact female Cyp1b1-/- and ovariectomized mice. 2-Methoxyestradiol also reduced Ang II-induced increase in blood pressure, water intake, urine output, and proteinuria in Cyp1b1+/+ male mice. Treatment with 2-methoxyestradiol attenuated Ang II-induced end-organ damage in intact Cyp1b1-/- and ovariectomized Cyp1b1+/+ and Cyp1b1-/- female mice and Cyp1b1+/+ male mice. 2-Methoxyestradiol mitigated Ang II-induced increase in urinary excretion of angiotensinogen in intact Cyp1b1-/- and ovariectomized Cyp1b1+/+ and Cyp1b1-/- female mice but not in Cyp1b1+/+ male mice. The G protein-coupled estrogen receptor 1 antagonist G-15 failed to alter Ang II-induced increases in blood pressure and renal function in Cyp1b1+/+ female mice. These data suggest that 2-methoxyestradiol reduces Ang II-induced hypertension and associated end-organ damage in intact Cyp1b1-/-, ovariectomized Cyp1b1+/+ and Cyp1b1-/- female mice, and Cyp1b1+/+ male mice independent of G protein-coupled estrogen receptor 1. Therefore, 2-methoxyestradiol could serve as a therapeutic agent for treating hypertension and associated pathogenesis in postmenopausal females, and in males.
Asunto(s)
Angiotensina II/farmacología , Citocromo P-450 CYP1B1/efectos de los fármacos , Estradiol/análogos & derivados , Hipertensión/tratamiento farmacológico , Enfermedades Renales/tratamiento farmacológico , Especies Reactivas de Oxígeno/metabolismo , 2-Metoxiestradiol , Animales , Presión Sanguínea/efectos de los fármacos , Determinación de la Presión Sanguínea , Citocromo P-450 CYP1B1/metabolismo , Modelos Animales de Enfermedad , Estradiol/farmacología , Femenino , Hipertensión/inducido químicamente , Enfermedades Renales/patología , Pruebas de Función Renal , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Ovariectomía/métodos , Distribución Aleatoria , Sensibilidad y Especificidad , Factores SexualesRESUMEN
The aim of this study was to determine the frequencies of chromosomal aberrations (CA) and cytochalasin-blocked micronuclei (CBMN) in peripheral blood lymphocytes from Turkish coke oven workers and the influence of CYP1A1, CYP1B1, EPHX1, GSTM1, GSTT1, and GSTP1 gene polymorphisms on these biomarkers. Cytogenetic analysis showed that occupational exposure significantly increased the CA and CBMN frequencies. Gene polymorphisms, on the other hand, did not affect CA or CBMN in either exposed or control subjects. However, due to the limited sample size, our findings need to be verified in future studies with a larger sample.